Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "inflammatory"

216 News Found

Bronchoscopic Thermal Vapor Ablation (BTVA): A new ray of hope for COPD patients
Hospitals | March 31, 2022

Bronchoscopic Thermal Vapor Ablation (BTVA): A new ray of hope for COPD patients

Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India


Cipla Medpro South Africa partners with mAbxience for affordable cancer drugs
News | March 31, 2022

Cipla Medpro South Africa partners with mAbxience for affordable cancer drugs

The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication


Sanofi and IGM Biosciences team up to commercialise IgM antibody agonists
Biotech | March 30, 2022

Sanofi and IGM Biosciences team up to commercialise IgM antibody agonists

Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets


Dupixent is a star in Sanofi’s immunology strategy
Biotech | March 29, 2022

Dupixent is a star in Sanofi’s immunology strategy

Dupixent peak sales ambition raised to more than €13 billion


Merck KGaA reports higher profits on strong volumes across its businesses
News | March 03, 2022

Merck KGaA reports higher profits on strong volumes across its businesses

Company expects strong organic growth in sales, EBITDA in 2022


Cannabotech's IntegrativePain products reduce pain considerably
Biotech | February 28, 2022

Cannabotech's IntegrativePain products reduce pain considerably

The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022


Cantex and Harvard's Wyss Institute to expand development of Azeliragon
News | February 27, 2022

Cantex and Harvard's Wyss Institute to expand development of Azeliragon

Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.


Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb
Biotech | February 25, 2022

Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb

It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).


Resolution Therapeutics strengthens its team with two new appointments
People | February 20, 2022

Resolution Therapeutics strengthens its team with two new appointments

Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance


Ribon Therapeutics appoints Prakash Raman as President and CEO
People | February 18, 2022

Ribon Therapeutics appoints Prakash Raman as President and CEO

Dr. Raman has succeeded Victoria Richon